Pharnext
Ali Shamsali, Pharm.D. has a work experience that includes roles in various pharmaceutical companies. From 2019 to 2020, they served as the Clinical Operations Lead at Zentalis Pharmaceuticals. Prior to that, from 2017 to 2019, they worked at Novartis as the US Oncology Clinical Trial Lead. From 2015 to 2018, they held the position of Senior Medical Affairs Consultant at Aitero Inc.
Ali Shamsali obtained a Doctor of Pharmacy (Pharm.D.) degree from Albany College of Pharmacy and Health Sciences. No further information is provided regarding the duration of the program or any additional fields of study.
This person is not in any offices
Pharnext
Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.